Renal cancer vaccine - FBM Pharma

Drug Profile

Renal cancer vaccine - FBM Pharma

Alternative Names: Renal cancer vaccine - LipoNova; Renal cancer vaccine - Vaccentis; Reniale

Latest Information Update: 10 Sep 2015

Price : $50

At a glance

  • Originator Liponova AG
  • Developer FBM-PHARMA
  • Class Cancer vaccines; Tumour cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity No

Highest Development Phases

  • Marketed Renal cancer

Most Recent Events

  • 15 Jun 2015 Renal cancer vaccine is still in phase-III development in the EU
  • 08 Feb 2014 Registered for Renal cancer (adjuvant therapy) in Austria (Intradermal) - First global approval
  • 27 Nov 2007 LipoNova signs Memorandum of Understanding for the development and marketing of Reniale® with an undisclosed non-European company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top